Abstract
Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Current Pharmaceutical Design
Title:Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease
Volume: 24 Issue: 17
Author(s): Seyed Mostafa Parizadeh, Maryam Ghandehari, Motahareh Heydari-majd, Sima Seifi, Ramin Mardani, Seyed Mohamadreza Parizadeh, Majid Ghayour-Mobarhan, Gordon A. Ferns, Seyed Mahdi Hassanian*Amir Avan*
Affiliation:
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
- Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Cardiovascular disease, immune system, Toll-like receptors, signaling pathway, atherogenesis, stroke.
Abstract: Cardiovascular Disease (CVD) is one of the most important causes of morbidity and mortality, and associated with an important economic burden globally. Over the last decade, the prevalence of CVD has been rising globally, and is now associated with millions of death annually in both developed and developing countries. There is good evidence that the immune system is involved in the pathophysiology of CVD. Toll-like receptors (TLRs) and their down-stream signaling pathways play an important role in the immune system. Recent studies have suggested that the TLRs are involved in atherogenesis, including stroke, myocardial infarction, ischemiareperfusion injury, cardiac remodeling and development of Heart Failure (HF). In this review we have summarized the recent studies investigating the role of TLRs in CVD and the potential for using TLRs signaling pathways as a therapeutic target in CVD.
Export Options
About this article
Cite this article as:
Parizadeh Mostafa Seyed , Ghandehari Maryam , Heydari-majd Motahareh , Seifi Sima , Mardani Ramin , Parizadeh Mohamadreza Seyed , Ghayour-Mobarhan Majid , Ferns A. Gordon , Hassanian Mahdi Seyed *, Avan Amir *, Toll-like Receptors Signaling Pathways as a Potential Therapeutic Target in Cardiovascular Disease, Current Pharmaceutical Design 2018; 24 (17) . https://dx.doi.org/10.2174/1381612824666180614090224
DOI https://dx.doi.org/10.2174/1381612824666180614090224 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Altered Expression of microRNAs in Serum Extracellular Vesicles in Rats with Severe Burns during Shock Stage
Current Molecular Medicine Diagnosis and Management of Heart Failure with Preserved Ejection Fraction: 10 Key Lessons
Current Cardiology Reviews Membrane Lipids in the Function of Serotonin and Adrenergic Receptors
Current Medicinal Chemistry Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Justification of Increasing the Blood Flow Velocity in the Arteries of the Thyroid Gland in Autoimmune Thyroiditis as a Reflection of Endothelial Changes Due to Inflammatory Status
Current Medical Imaging Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design ENaC and Its Regulatory Proteins as Drug Targets for Blood Pressure Control
Current Drug Targets Marine n-3 Fatty Acids for Cardiovascular Risk Reduction and Disease Control in Rheumatoid Arthritis: “Kill Two Birds with One Stone”?
Current Pharmaceutical Design Acute Cerebral Blood Flow Variations after Human Cardiac Arrest Assessed by Stable Xenon Enhanced Computed Tomography
Current Neurovascular Research Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives
Current Medicinal Chemistry Allosteric Modulators of Class B G-Protein-Coupled Receptors
Current Neuropharmacology SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Centenarian Offspring: A Model for Understanding Longevity
Current Vascular Pharmacology Overview of Pediatric Epilepsy
Current Pediatric Reviews “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Therapeutic Potential and Strategies Against Leukocyte-Platelet Interaction in Atherosclerosis
Current Vascular Pharmacology Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology